洞察心力衰竭与保存的射出小部分和睡眠呼吸障碍的相互作用
Michael Wester1, Michael Arzt1, Frederick Sinha1
1Department of Internal Medicine II, University Hospital Regensburg, 93053 Regensburg, Germany.
Biomedicines
|November 25, 2023
概括
保持喷射分数 (HFpEF) 的心力衰竭是一个越来越令人担忧的问题. 睡眠呼吸障碍 (SDB) 与肥胖的HFpEF表型有关,需要个性化治疗以获得更好的结果.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 遗传学 是一个遗传学.
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭带来了重大的全球健康和经济挑战.
- 对HFpEF的有限治疗选择源于其不同的病因及其独特的患者表型.
- 睡眠呼吸障碍 (SDB) 是一种常见的并发症,经常与肥胖的HFpEF表型相关.
研究的目的:
- 审查HFpEF的常见病因和表型,特别关注SDB的作用.
- 突出需要个性化治疗策略,超越一般的HFpEF治疗.
- 探索SDB和针对性治疗的肥胖HFpEF表型之间的机制联系.
主要方法:
- 对HFpEF病因,表型和并发症的现有文献的审查.
- 对识别HFpEF表型的集群分析的分析.
- 讨论SDB和HFpEF之间的相互作用,特别是在肥胖患者中.
主要成果:
- HFpEF表现出多样化的表型,SDB是肥胖子组中的一个重要因素.
- 目前的一般HFpEF疗法表现出有限的成功,强调了需要量身定制的方法.
- 了解SDB和HFpEF之间的共享机制对于开发有效的治疗方法至关重要.
结论:
- 个性化治疗策略对于管理HFpEF至关重要,特别是对于特定的表型,如患有SDB的肥胖患者.
- 进一步研究SDB和HFpEF之间的机制平行将为精准医学铺平道路.
- 像单细胞转录组学和基因编辑等先进技术为了解HFpEF病理机制提供了新的途径.
相关概念视频
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:21Sleep Apnea
159
Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
The condition is more prevalent among...
159
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
01:22Heart Failure Drugs: Diuretics
396
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
396
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
01:22Heart Failure Drugs: β-Blockers
342
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
342